Hikma Pharmaceuticals PLC (HKMPY)
OTHER OTC:HKMPY

Hikma Pharmaceuticals Stock Analysis & Ratings

HKMPY Stock Chart & Stats

Day’s Range$44.63 - $44.632
52-Week Range$41.08 - $75.81
Previous Close$42.3
Volume365.00
Average Volume (3M)1.50K
Market Cap$4.98B
P/E Ratio11.8
Beta0.06
Next EarningsAug 04, 2022
EPS ForecastN/A
Dividend Yield1.04 (2.44%)
1Y Price TargetN/A
Smart Score3
EPS (TTM)3.66


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

HKMPY FAQ

What was Hikma Pharmaceuticals’s price range in the past 12 months?
Hikma Pharmaceuticals lowest stock price was $41.08 and its highest was $75.81 in the past 12 months.
    What is Hikma Pharmaceuticals’s market cap?
    Hikma Pharmaceuticals’s market cap is $4.98B.
      What is Hikma Pharmaceuticals’s price target?
      Currently, no data Available
      What do analysts say about Hikma Pharmaceuticals?
      Not enough analysts have published a price target to provide an average price target.
      When is Hikma Pharmaceuticals’s upcoming earnings report date?
      Hikma Pharmaceuticals’s upcoming earnings report date is Aug 04, 2022 which is in 75 days.
        How were Hikma Pharmaceuticals’s earnings last quarter?
        Hikma Pharmaceuticals released its earnings results on Feb 24, 2022. The company reported $1.512 earnings per share for the quarter, beating the consensus estimate of N/A by $1.512.
          Is Hikma Pharmaceuticals overvalued?
          According to Wall Street analysts Hikma Pharmaceuticals’s price is currently Overvalued.
            Does Hikma Pharmaceuticals pay dividends?
            Hikma Pharmaceuticals pays a Semiannually dividend of $0.7 which represents an annual dividend yield of 2.44%. Hikma Pharmaceuticals’s last Semiannually dividend payment was on May 09, 2022. Hikma Pharmaceuticals’s upcoming ex-dividend date is Mar 17, 2022
              What is Hikma Pharmaceuticals’s EPS estimate?
              Hikma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Hikma Pharmaceuticals have?
              Hikma Pharmaceuticals has 111,600,000 shares outstanding.
                What happened to Hikma Pharmaceuticals’s price movement after its last earnings report?
                Hikma Pharmaceuticals reported an EPS of $1.512 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -10.82%.
                  Which hedge fund is a major shareholder of Hikma Pharmaceuticals?
                  Currently, no hedge funds are holding shares in HKMPY

                  ---

                  Hikma Pharmaceuticals Stock Analysis

                  Smart Score
                  3
                  Underperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  Price Target
                  No data currently available
                  The Hikma Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Hikma Pharmaceuticals PLC

                  Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and are sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd. and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Henkel AG
                  Guangdong Investment

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis